Alfieri Michael’s Insider Buy Signals Confidence in Aldeira’s Rare‑Disorder Therapy
Alfieri Michael’s insider buy of 5,000 Aldeira shares signals confidence in its orphan‑drug pipeline, suggesting potential upside despite recent FDA setbacks.
4 minutes to read